GR has been found expressed at low levels in primary prostate tumors from PCa patients; however, its expression increases as tumors develop metastasis and resistance to anti-androgen therapy and taxane chemotherapy [8,9,142,143]. This evidence concerns the gene NR3C1 and posterior cortical atrophy.